Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017
Ahmed Babiker, Lloyd Clarke, Melissa Saul, et al.
Clinical Infectious Diseases (2020) Vol. 73, Iss. 11, pp. e4521-e4530
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Navigating Available Treatment Options for Carbapenem-ResistantAcinetobacter baumannii-calcoaceticusComplex Infections
Ryan K. Shields, David L. Paterson, Pranita D. Tamma
Clinical Infectious Diseases (2023) Vol. 76, Iss. Supplement_2, pp. S179-S193
Open Access | Times Cited: 73
Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network
Qi Wang, Longyang Jin, Shijun Sun, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 61
Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
Jacinda C. Abdul‐Mutakabbir, Nicole Griffith, Ryan K. Shields, et al.
Infectious Diseases and Therapy (2021) Vol. 10, Iss. 4, pp. 2177-2202
Open Access | Times Cited: 46
Treatment of carbapenem-resistantPseudomonas aeruginosainfections: a case for cefiderocol
Rafael Cantón, Yohei Doi, Patricia J. Simner
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 8, pp. 1077-1094
Open Access | Times Cited: 36
The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
Abdullah Tarık Aslan, Murat Akova
Antibiotics (2022) Vol. 11, Iss. 2, pp. 277-277
Open Access | Times Cited: 32
Ceftazidime/Avibactam versus Polymyxin B in the Challenge of Carbapenem-Resistant Pseudomonas aeruginosa Infection
Juan Chen, Qiqiang Liang, Xinyi Chen, et al.
Infection and Drug Resistance (2022) Vol. Volume 15, pp. 655-667
Open Access | Times Cited: 31
Epidemiology and outcomes associated with carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa: a retrospective cohort study
Amanda Vivo, Margaret A. Fitzpatrick, Katie J. Suda, et al.
BMC Infectious Diseases (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 30
Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant Pseudomonas aeruginosa Bacteremia or Pneumonia
Sunish Shah, Ellen G Kline, Ghady Haidar, et al.
Clinical Infectious Diseases (2024) Vol. 80, Iss. 1, pp. 24-28
Open Access | Times Cited: 6
Comparison of carbapenem-susceptible and carbapenem-resistant Enterobacterales at nine sites in the USA, 2013–2016: a resource for antimicrobial resistance investigators
Joseph D. Lutgring, Alyssa G. Kent, Jolene R. Bowers, et al.
Microbial Genomics (2023) Vol. 9, Iss. 11
Open Access | Times Cited: 13
Computational investigation of amide derivative as potential anti-carbapenem-resistant Pseudomonas aeruginosa
Sopuruchukwu E. Ogbodo, Osarob U. Edeghor, Chioma U. Benson, et al.
Journal of the Indian Chemical Society (2024) Vol. 101, Iss. 8, pp. 101184-101184
Closed Access | Times Cited: 4
From Gram-Negative Strains to Mortality: Understanding Bacterial Resistance in Mainland China
Yi‐Chang Zhao, Zhihua Sun, Jiakai Li, et al.
Research Square (Research Square) (2025)
Closed Access
Tailor-Engineered nano-diagnostic platform for polymyxin B monitoring and its biological application based on molecularly imprinted Sulphur-doping graphene quantum dot–derived
Siyuan Li, LiXia LI, Xiaohui Huang, et al.
Chemical Engineering Journal (2025), pp. 161122-161122
Closed Access
Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study
Zhenwei Yu, Huangdu Hu, Xiaofen Liu, et al.
Antimicrobial Agents and Chemotherapy (2025)
Open Access
Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
Nicholas Rebold, Abdalhamid M Lagnf, Sara Alosaimy, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 12
Severe infections caused by difficult-to-treat Gram-negative bacteria
Silvia Dettori, Federica Portunato, Antonio Vena, et al.
Current Opinion in Critical Care (2023) Vol. 29, Iss. 5, pp. 438-445
Open Access | Times Cited: 12
Efficacy and mortality of ceftazidime/avibactam-based regimens in carbapenem-resistant Gram-negative bacteria infections: A retrospective multicenter observational study
Haihui Zhuang, Ying Chen, Qin Hu, et al.
Journal of Infection and Public Health (2023) Vol. 16, Iss. 6, pp. 938-947
Open Access | Times Cited: 9
Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients
Jean‐François Timsit, Paul-Henri Wicky, Étienne de Montmollin
Antibiotics (2022) Vol. 11, Iss. 2, pp. 144-144
Open Access | Times Cited: 14
A potential strategy against clinical carbapenem-resistant Enterobacteriaceae: antimicrobial activity study of sweetener-decorated gold nanoparticles in vitro and in vivo
Haifeng Liu, Zeyu Huang, Huanchang Chen, et al.
Journal of Nanobiotechnology (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 8
Rapid Detection of Carbapenemases Using NG-Test® CARBA 5 in Positive Blood Cultures: A Diagnostic Test Study
Diana Munguia-Ramos, Luis Fernando Xancal-Salvador, Veronica Esteban-‬Kenel, et al.
Antibiotics (2024) Vol. 13, Iss. 11, pp. 1105-1105
Open Access | Times Cited: 2
Anti-adhesion and antibiofilm activities of Lavandula mairei humbert essential oil against Acinetobacter baumannii isolated from hospital intensive care units
Raja El Kheloui, Asma Laktib, Soufiane Elmegdar, et al.
Biofouling (2022) Vol. 38, Iss. 10, pp. 953-964
Closed Access | Times Cited: 9
Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection
Zihao Zheng, Ziqiang Shao, Lihai Lu, et al.
BMC Infectious Diseases (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales
Jessica Howard‐Anderson, Michelle Earley, Lauren Komarow, et al.
Infection Control and Hospital Epidemiology (2022) Vol. 43, Iss. 12, pp. 1840-1846
Open Access | Times Cited: 8
The Burden and Impact of Early Post-transplant Multidrug-Resistant Organism Detection Among Renal Transplant Recipients, 2005–2021
Ahmed Babiker, Geeta Karadkhele, Andrei Bombin, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 3
Open Access | Times Cited: 1
Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study
Keyang Li, Debao Li, Hongliang Dong, et al.
Infection and Drug Resistance (2024) Vol. Volume 17, pp. 1281-1289
Open Access | Times Cited: 1
Incidence, risk factors and clinical outcome of multidrug-resistant organisms after heart transplantation
Sophia Hatzianastasiou, Paraskevas Vlachos, G Stravopodis, et al.
World Journal of Transplantation (2024) Vol. 14, Iss. 2
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top